Percheron Therapeutics (ASX:PER) has entered into a worldwide exclusive license agreement with Hummingbird Bioscience, a venture-backed biotechnology company based in Singapore, for HMBD-002, a monoclonal antibody therapy with potential applications in various cancer indications. …
Percheron licenses Phase 2 ready immuno-oncology candidate from Hummingbird
June 27, 2025 Australian Biotech
Latest Video
New Stories
-
BMS therapy secures Australian approval for psoriatic arthritis
September 3, 2026 - -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - -
ENA Respiratory secures funding to test antiviral nasal spray in people with asthma
September 2, 2026 - -
OncoSil pursues a reimbursement pathway as it prepares for US rollout
September 2, 2026 - - Australian Biotech -
Vitrafy takes its cryopreservation technology into the US cell therapy market
September 2, 2026 - - Australian Biotech